BDSX: Falling Wedge detected on 23 Oct 2026

Biodesix is forming a falling wedge pattern on strong technical structure (14.0/15) with moderate breakout quality (13.0/13) and solid volume confirmation (10.0/12), yielding an overall pattern quality score of 73. The stock trades at $23.94, sandwiched between key support at $21.24 and resistance at $23.89—just 1 cent below current price. Volume is elevated at 138,543 shares (1.4x average), supporting pattern integrity. RSI at 39.78 indicates mild oversold conditions. The measured move target sits at $25.39 with an 85% win probability.

Biodesix delivered Q2 2026 results showing $26.9 million in revenue (+34% YoY) with 82% gross margin and 42% growth in diagnostic testing revenue. Diagnostic testing volumes grew 38% year-over-year while operating expenses grew only 7%, demonstrating 56% improvement in Adjusted EBITDA. Test volume growth reflected broad adoption from primary care (up 133%) and pulmonology (up 31%). The company maintained FY 2026 revenue guidance of $108-114 million (25% mid-point growth). Recent momentum includes presentations at CHEST 2026 in October highlighting clinical utility and diagnostic test sequencing. The Healthcare sector is in bullish regime (0.75), providing tailwind for this diagnostic solutions business. Q3 results are scheduled for November 5, 2026 at 4:30 p.m. ET, a catalyst just 13 days away.

A successful falling wedge breakout targets $25.39 (conservative measure), representing 6.1% upside from current $23.94 price. The pattern suggests conviction once resistance at $23.89 is cleared on sustained volume. Historical data shows 85% win probability for this configuration. Invalidation occurs below support at $21.24 (12.3% downside risk), which would signal pattern failure and warrant reassessment. Volume should remain elevated (>120k shares) during breakout to confirm institutional participation. ATR of $1.67 (6.98% of price) indicates this move fits normal volatility parameters.

Immediate catalyst risk: Q3 earnings on November 5 could trigger sharp directional move before pattern completes. Sales force expansion lagged expectations in Q2 (104 reps vs. plan), raising near-term revenue momentum questions. Stock has declined 18.27% over the past month despite strong fundamentals, suggesting institutional distribution or sector rotation. MACD histogram negative (-0.3412) indicates weakening momentum despite bullish structure. Recent history shows two prior weak patterns (bull flag on 2026-08-06, rounding bottom on 2026-02-05), signaling pattern formation struggles. Beta of 0.8 provides some downside cushion, but elevated 20-day volatility (55.9%) creates whipsaw risk. RSI at 39.78 leaves room to fall further before true oversold conditions emerge.

We scan more than 6,000 NYSE and NASDAQ stocks every trading day and compare each detected pattern against a database of 370,000+ historical detections. Every setup is scored across three dimensions: Structure, Volume, and Breakout Readiness. Win probability is a calibrated estimate of how similar historical setups performed over the following 10 trading days. This is a swing trading tool built for multi-day holds. It is not built or tested for day trading.